UP0.F Ultragenyx Pharmaceutical Inc

Healthcare Biotechnology Frankfurt Exchange
14.81 EUR
Close of Nov 13, 2026
11.19 34.00
Market cap
EUR 1.51B
P/E
-
P/B
19.57x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is UP0.F undervalued?

Graham number

The Graham number of Ultragenyx Pharmaceutical Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ultragenyx Pharmaceutical Inc fundamental analysis

No fundamental analysis for Ultragenyx Pharmaceutical Inc yet.

Ultragenyx Pharmaceutical Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced …

Full company profile